Compare Gilead Sciences, Inc. (GILD) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Texas Instruments Incorporated — how do they compare? Gilead Sciences, Inc. trades at $135.84 (market cap $163.51B), while Texas Instruments Incorporated trades at $289.63 (market cap $274.11B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TXN | |
|---|---|---|
Market Cap | $163.51B | $274.11B |
Sector | Health | Technology |
52-Week High | $155.80 | $332.35 |
52-Week Low | $108.22 | $153.33 |
Enterprise Value | $178.05B | $283.06B |
Dividend Yield | 2.49% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Texas Instruments (TXN) trades at $305.55, up 2.34% with a bullish technical signal. Recent Q1 2026 earnings beat expectations, with revenue growth to $17.68 billion in 2025. The company maintains strong profitability with 29.11% net margin and announced a CFO transition with Julie Knecht succeeding Rafael Lizardi in August 2026. Analysts show a buy consensus with a $317.20 price target, though valuation ratios like P/E of 52.23 appear elevated.
Outlook remains positive driven by AI data center demand and 300mm capacity expansion, but risks include high debt-to-asset ratio of 40.61% and competitive pressures. The stock presents growth potential with disciplined risk management advised given premium valuation and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
